Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.195
+$0.045 · +3.91%
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Regular session
$1.195
+$0.045 · +3.91%
Regular session · ET · Market data may be delayed.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Day range
Current $1.195
52-week range
Current $1.195
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
36
Expensive
Sentiment
41
Mixed
Risk
63
High Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Day range
Current $1.195
52-week range
Current $1.195
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 25.21M USD | 52.3M USD | 44.76M USD | 17.2M USD | 243K USD |
| Cost of goods sold | 5.32M USD | — | 94.4M USD | 1.73M USD | 387K USD |
| Gross profit | 19.89M USD | 52.3M USD | −49.65M USD | 15.47M USD | −144K USD |
| Research and development | 94.43M USD | 109.18M USD | 94.4M USD | 43.14M USD | 14.48M USD |
| Selling, general, and administrative | 26.79M USD | 32.02M USD | 28.85M USD | 18.7M USD | 9.71M USD |
| Operating expenses | 115.91M USD | 141.2M USD | 28.85M USD | 60.11M USD | 23.8M USD |
| Interest income | 9.47M USD | 14.72M USD | 15.47M USD | 3.42M USD | 43K USD |
| Interest expense | — | — | — | 98K USD | 302K USD |
| Depreciation and amortization | 5.32M USD | 5.41M USD | 4.21M USD | 1.73M USD | 387K USD |
| Operating income | −96.01M USD | −88.9M USD | −78.49M USD | −44.64M USD | −23.95M USD |
| Net income | −87.87M USD | −78.06M USD | −68.26M USD | −43.59M USD | −21.44M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$14.50
1113.39% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
